Figure 7: Arginase Activity and ROS Production Are Increased in RBCs From Patients With Type 2 Diabetes

(A) Arginase activity in RBCs from healthy subjects (HS, n = 9) and patients with type 2 diabetes (DM) (n = 9). (B to G) ROS production determined by electron spin resonance in RBCs from HS and DM (B) under basal condition (HS n = 6 and DM n = 6), (C) following incubation with vehicle (Veh) or the ROS scavenger NAC (1 mmol/l, HS n = 6 and DM n = 6), (D) following incubation with vehicle or the arginase inhibitor nor-NOHA (0.1 mmol/l, HS n = 6 and DM n = 6), (E) following incubation with vehicle or the nonselective NOS inhibitor L-NAME (0.1 mmol/l, HS n = 6 and DM n = 6), (F) following incubation with vehicle or the iNOS inhibitor 1400W (0.1 mmol/l, HS n = 5 and DM n = 6), and (G) following incubation with vehicle or L-arginine (L-Arg) (3 mmol/l, HS n = 6 and DM n = 6). Significant differences from vehicle or WT RBCs are shown; *p < 0.05, **p < 0.01 and ***p < 0.001. Abbreviations as in Figures 1, 2, and 4.